Skip to main content

Table 1 Study Population Demographics and Outcomes, Anchorage, Alaska 2009–2011 (N = 488 total specimens)

From: Human papillomavirus (HPV) types among Alaska native women attending a colposcopy clinic in Anchorage, Alaska, 2009–2011

 N (%)Mean (Standard Deviation)
Age Group
  < 25 yrs194 (40%)29.7 yrs. (9.4 yrs)
 25–29 yrs124 (25%) 
 30–34 yrs78 (16%) 
 35–39 yrs34 (7%) 
 40–44 yrs20 (4%) 
 45–49 yrs13 (3%) 
  ≥ 50 yrs25 (5%) 
Ethnic Group
 Eskimo238 (49%) 
 Indian149 (31%) 
 Aleut73 (15%) 
 Mixed17 (3%) 
 Non-Native9 (2%) 
 Non-specific Native2 (0.4%) 
Tobacco use, ever246/484 (51%) 
Current tobacco user225/471 (48%) 
Number of HPV vaccine doses
 0440 (90%) 
 118 (3.7%) 
 29 (1.8%) 
 320 (4.1%) 
 41 (0.2%) 
Ectocervical biopsy done438 (90%) 
Endocervical curettage done402 (82%) 
Loop Electrosurgical Excision Procedure done42 (8.6%) 
Cytology Referral Diagnosis
 Atypical Squamous Cells of Undetermined Significance231 (47%) 
 Low-grade Squamous Intraepithelial Lesion162 (33%) 
 High-grade Squamous Intraepithelial Lesion46 (9%) 
 Atypical Squamous Cells cannot exclude High-Grade Squamous Intraepithelial cells25 (5%) 
 Unknown24 (5%) 
Final Pathology Diagnosis
 CIN* 322 (5%) 
 CIN 245 (9%) 
 CIN 1184 (38%) 
 Metaplasia/Inflammation135 (28%) 
 Other**46 (9%) 
Insufficient/No biopsy55 (11%) 
Number of HPV types in HPV positive specimens
 1126 (28%)2.6 (SD = 1.57)
 2126 (28%)Median = 2
 394 (21%) 
 455 (12%) 
 531 (7%) 
 6+26 (6%) 
Number of 9-valent HPV vaccine types present
 0184 (38%)0.88 (SD = 0.87)
 1205 (42%) 
 276 (16%) 
 319 (4%) 
 44 (0.8%) 
  1. *CIN Cervical intraepithelial neoplasia
  2. ** Other = Atrophy, Atypia, Negative